Gains in the current understanding of managing neovascular AMD with brolucizumab
Abstract Background Unresolved retinal fluid and high injection burden are major challenges for patients with neovascular age-related macular degeneration.Brolucizumab addresses these challenges by providing robust vision gains and superior fluid resolution, with the potential for longer treatment intervals.Brolucizumab has been associated with adv